Skip to content

BioNexus Gene Lab Corp.: 10-Q filed 2020-08-11

What BioNexus Gene Lab Corp. reported in its quarterly report filed 2020-08-11 (fiscal Q2 2020): 30 published measures, 82 facts as tagged in accession 0001477932-20-004715.

This filing

Form
10-Q (quarterly report)
Filed
2020-08-11
Fiscal period
fiscal Q2 2020
Accession
0001477932-20-004715 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BioNexus Gene Lab Corp. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2020-06-301,060,241USD
At 2019-12-311,231,236USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2020-06-3090,558USD
At 2019-12-31108,872USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2020-06-30969,683USD
At 2020-03-311,032,734USD
At 2019-12-311,122,364USD
At 2018-12-311,521,926USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2020-06-30728,490USD
At 2019-12-31859,076USD
At 2019-06-301,140,387USD
At 2018-12-311,260,239USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-66,537USD91
2020-01-01 to 2020-06-30-114,490USD182
2020-01-01 to 2020-03-31-47,953USD91
2019-01-01 to 2019-12-31-246,469USD365
2019-04-01 to 2019-06-30-70,398USD91
2019-01-01 to 2019-06-30-131,865USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-97,941USD182
2019-01-01 to 2019-06-30-101,496USD181

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2020-01-01 to 2020-06-300USD182
2019-01-01 to 2019-06-309,204USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2020-04-01 to 2020-06-306,541USD91
2020-01-01 to 2020-06-306,541USD182
2019-04-01 to 2019-06-3021,645USD91
2019-01-01 to 2019-06-3049,733USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-7,975USD182
2019-01-01 to 2019-06-30-8,701USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2020-01-01 to 2020-06-300USD182
2019-01-01 to 2019-06-30-9,204USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2020-06-30-447,801USD
At 2019-12-31-333,311USD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2020-04-01 to 2020-06-30487USD91
2020-01-01 to 2020-06-301,347USD182
2019-04-01 to 2019-06-301,179USD91
2019-01-01 to 2019-06-302,443USD181

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2020-06-30279,018USD
At 2019-12-31312,908USD

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-66,050USD91
2020-01-01 to 2020-06-30-113,143USD182
2019-04-01 to 2019-06-30-69,219USD91
2019-01-01 to 2019-06-30-129,422USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2020-06-30762,753USD
At 2019-12-31882,571USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2020-06-3046,452USD
At 2019-12-3151,574USD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2020-06-3021,097USD
At 2019-12-317,580USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-10,774USD91
2020-01-01 to 2020-06-30-23,767USD182
2019-04-01 to 2019-06-304,625USD91
2019-01-01 to 2019-06-3013,891USD181

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2020-04-01 to 2020-06-3017,315USD91
2020-01-01 to 2020-06-3030,308USD182
2019-04-01 to 2019-06-3017,020USD91
2019-01-01 to 2019-06-3035,842USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2020-06-30102,730,891shares
At 2019-12-31102,730,891shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2020-06-30-5,011,891USD
At 2019-12-31-5,011,891USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2020-06-30-55,294USD
At 2019-12-31-17,103USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2020-06-3016,645USD
At 2019-12-3123,542USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2020-06-30404,991USD
At 2019-12-31404,991USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2020-06-30118,478USD
At 2019-12-3198,219USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2020-04-01 to 2020-06-30-63,051USD91
2020-01-01 to 2020-06-30-152,681USD182
2019-04-01 to 2019-06-30-87,998USD91
2019-01-01 to 2019-06-30-132,320USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2020-04-01 to 2020-06-3058,183USD91
2020-01-01 to 2020-06-3097,028USD182
2019-04-01 to 2019-06-3081,224USD91
2019-01-01 to 2019-06-30157,712USD181

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2020-01-01 to 2020-06-3020,259USD182
2019-01-01 to 2019-06-3020,954USD181

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-1,361USD182
2019-01-01 to 2019-06-30-1,491USD181

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2020-01-01 to 2020-06-30-13,517USD182
2019-01-01 to 2019-06-309,360USD181

Inspect the source

Entity
BioNexus Gene Lab Corp. / CIK 0001737523
Captured
2026-09-21T17:25:37.348Z
SEC response SHA-256
eebcf668b9e42f0c31bf1fe5b3c17450d7f4d836f715c9cebcc6a4fafbcff983

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001737523.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))